Thermo Fisher Scientific (TMO) Equity Income (2021 - 2026)

Thermo Fisher Scientific (TMO) has reported Equity Income for 6 consecutive years, with -$15.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Equity Income fell 850.0% year-over-year to -$15.0 million; the trailing twelve-month figure through Jun 2026 stood at -$53.0 million (down 857.14% YoY), and the FY2025 full-year result was -$41.0 million, up 2.38% from the prior year.
• Equity Income retreated to -$15.0 million in Q2 2026 per TMO's latest filing, from -$8.0 million in the prior quarter.
• Across five years, Equity Income topped out at $33.0 million in Q4 2024 and bottomed at -$84.0 million in Q2 2024.
• Historically, Equity Income has averaged -$18.8 million across 5 years, with a median of -$15.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Equity Income sank 5000.0% in 2022, then jumped 3400.0% in 2024.
• Over 5 years, Equity Income stood at -$30.0 million in 2022, then surged by 96.67% to -$1.0 million in 2023, then surged by 3400.0% to $33.0 million in 2024, then sank by 196.97% to -$32.0 million in 2025, then soared by 53.12% to -$15.0 million in 2026.
• According to Business Quant data, Equity Income over the past three periods registered -$15.0 million, -$8.0 million, and -$32.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.